Phosphodiesterase 5 Inhibition Protects Against Increased Intra-Abdominal Pressure-Induced Renal Dysfunction in Experimental Congestive Heart Failure

Abstract

Decompensated CHF and MI rats are vulnerable to the adverse renal effects of IAP. Tadalafil abolishes IAP-induced renal dysfunction, supporting a therapeutic role for PDE5 inhibition in CHF associated with ascites.